Immuneering Corporation

NasdaqGM IMRX

Immuneering Corporation Price to Earnings Ratio (P/E) on January 14, 2025

Immuneering Corporation Price to Earnings Ratio (P/E) is NA on January 14, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Immuneering Corporation 52-week high Price to Earnings Ratio (P/E) is NA on January 14, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Immuneering Corporation 52-week low Price to Earnings Ratio (P/E) is NA on January 14, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Immuneering Corporation average Price to Earnings Ratio (P/E) for the last 52 weeks is NA.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: IMRX

Immuneering Corporation

CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	245 Main Street
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Key trends

Past 5 years